AI Analysis
AI-generated analysis. Always verify with the original filing.
IceCure Medical Ltd announced that the American Society of Breast Surgeons' 2026 Resource Guide update recommends cryoablation for selected patients with biologically low-risk early-stage breast cancer, citing IceCure’s ICE3 study and FDA Advisory Panel vote. This follows ProSense®'s FDA clearance in October 2025 for low-risk breast cancer in patients aged ≥70 years with tumors ≤1.5 cm.
Key Takeaways
1ASBrS 2026 Resource Guide recommends cryoablation for low-risk early-stage breast cancer
2ProSense® received FDA clearance October 2025 for low-risk breast cancer in patients ≥70 years, tumors ≤1.5 cm, with adjuvant endocrine therapy
3ProSense® is first and only FDA-cleared device for breast cancer treatment
4U.S. patient population for ProSense® breast cryoablation: ~200,000 women annually, including 47,245 low-risk breast cancer patients ≥70, 90,300 non-surgical candidates, 63,200 fibroadenoma patients
5ASBrS guide recognizes cryoablation for benign fibroadenomas and low-risk breast cancer in older patients